SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess
of $200,000 From Investment in Intercept Pharmaceuticals, Inc. to Contact
Brower Piven Before the April 22, 2014 Lead Plaintiff Deadline (ICPT)
STEVENSON, Md., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Brower Piven, A Professional
Corporation announces that a class action lawsuit has been commenced in the
United States District Court for the Southern District of New York on behalf
of purchasers of Intercept Pharmaceuticals, Inc. ("Intercept" or the
"Company") (Nasdaq:ICPT) securities during the period between January 9, 2014
and January 10, 2014, inclusive (the "Class Period").
If you have suffered a net loss from investment in Intercept securities
purchased on or after January 9, 2014 and held through the revelation of
negative information on January 10, 2014, as described below, you may obtain
additional information about this lawsuit and your ability to become a lead
plaintiff, at no cost to you, by contacting Brower Piven at
www.browerpiven.com, by email at firstname.lastname@example.org, by calling
410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley
Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined
experience litigating securities and class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply
to be appointed lead plaintiff no later than April 22, 2014 and be selected by
the Court. The lead plaintiff will direct the litigation and participate in
important decisions including whether to accept a settlement and how much of a
settlement to accept for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from investment in
Company units during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants' failure to disclose during the Class
Period that, while the efficacy primary endpoint in the study had already been
met, participants in the Phase 2 trial of its primary drug compound
obeticholic acid who received the drug suffered disproportionate levels of
lipid abnormalities. Following the revelation on January 10, 2014, after the
markets closed, by the National Institutes of Health that participants in the
study who received the drug suffered disproportionate levels of lipid
abnormalities, the value of Intercept shares significantly declined.
If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice. You
need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven
Brower Piven, A Professional Corporation
Press spacebar to pause and continue. Press esc to stop.